Zai Lab Limited ("Zai Lab" or the "Company") (NASDAQ: ZLAB; HKEX: 9688), an innovative, commercial-stage biopharmaceutical ...

Revenue was in line with analyst estimates. Earnings per share (EPS) surpassed analyst estimates by 46%. Looking ahead, ...

Zai Lab Ltd (HK:9688) has released an update. Zai Lab Ltd is set to offer 7,843,137 American Depositary Shares (ADS), representing 78,431,370 ...

Analyst Jonathan Chang from Leerink Partners reiterated a Buy rating on Zai Lab (ZLAB – Research Report) and keeping the price target at ...

Limited announced that it has commenced an underwritten public offering of $200M of American depositary shares, ADSs, each ...

Zai Lab and argenx have announced receipt of approval from the National Medical Products Administration (NMPA) of China for ...

Zai Lab Ltd (HK:9688) has released an update. Zai Lab Limited has announced a proposed follow-on underwritten public offering of $200 million ...

Zai Lab Ltd ( (ZLAB)) has released its Q3 earnings. Here is a breakdown of the information Zai Lab Ltd presented to its investors. Zai Lab Limited is a biopharmaceutical company based in China and the ...

First and only NMPA-approved treatment for patients with CIDP in China Second VYVGART Hytrulo indication approved in China November 11, 2024 – ...

Zai Lab Limited Unsponsored ADR (ZLAB) reported $102.27 million in revenue for the quarter ended September 2024, representing a year-over-year increase of 47.7%. EPS of -$0.42 for the same period ...

The business’s 50 day simple moving average is $25.16 and its 200 day simple moving average is $20.68. Zai Lab has a 1 year ...